Predictors of mortality in heart failure patients: a retrospective cohort study at a tertiary care hospital in Vadodara
DOI:
https://doi.org/10.18203/2320-6012.ijrms20253177Keywords:
Chronic kidney disease, Survival analysis, NT-proBNP, Mortality predictors, Heart failure, Left ventricular ejection fractionAbstract
Background: Heart failure (HF) remains a leading cause of morbidity and mortality worldwide, particularly in low- and middle-income countries. Understanding the factors contributing to mortality in HF patients can inform clinical decisions and improve patient outcomes. This study aims to identify the predictors of mortality in HF patients admitted to a tertiary care hospital in Vadodara, Gujarat.
Methods: This retrospective cohort study included 250 consecutive HF patients admitted to SSG Hospital, Vadodara, between January 2022 and December 2023. Patient data, including demographic characteristics, clinical features, comorbidities, left ventricular ejection fraction (LVEF), laboratory values and mortality outcomes, were collected from hospital records. Multivariable logistic regression was used to identify independent predictors of mortality. Kaplan-Meier survival curves were generated to analyze survival rates over the study period.
Results: The cohort consisted of 250 patients, with a mean age of 62.7±10.5 years. Males accounted for 58.9% of the cohort. Overall mortality was 29.3% during the follow-up period. Predictors of mortality included lower LVEF (OR 2.7, 95% CI 1.8-4.2, p<0.001), elevated NT-proBNP levels (OR 3.2, 95% CI 2.0-5.1, p<0.001) and chronic kidney disease (OR 2.5, 95% CI 1.6-4.0, p=0.002). Kaplan-Meier analysis revealed a significant difference in survival rates between patients with LVEF<40% and those with LVEF≥40% (p<0.001).
Conclusions: This study identified several key predictors of mortality in HF patients, including reduced LVEF, elevated NT-proBNP levels and chronic kidney disease. These findings underscore the need for close monitoring and management of these high-risk factors to improve survival outcomes in HF patients.
Metrics
References
Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS, et al. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2022;118(17):3272–87. DOI: https://doi.org/10.1093/cvr/cvac013
Rout S, Das S, Dihingia S, Biswas R. Prevalence of cardiac abnormalities and heart failure in India: An overview. Pharm J. 2025;7(2):128–34. DOI: https://doi.org/10.33545/26647591.2025.v7.i2a.128
Chaturvedi V. Heart failure in India: The INDUS (INDia Ukieri Study) Study. J Pract Cardiovasc Sci. 2020;6(1):28–33. DOI: https://doi.org/10.4103/2395-5414.182988
Comín-Colet J. Impact on clinical events and healthcare costs of adding telemedicine to multidisciplinary disease management programmes for heart failure: results of a randomized controlled trial. BMC Health Serv Res. 2016;16:246. DOI: https://doi.org/10.1177/1357633X15600583
Ponikowski P. Heart failure: preventing disease and death worldwide. Heart. 2014;100(3):176–85. DOI: https://doi.org/10.1002/2055-5822.12005
Chopra VK, Mittal S, Bansal M, Singh B, Trehan N. Clinical profile and one-year survival of patients with heart failure with reduced ejection fraction: the largest report from India. Indian Heart J. 2019;71(3):242–8. DOI: https://doi.org/10.1016/j.ihj.2019.07.008
Harikrishnan S, Jeemon P, Ganapathi S, Sivasankaran S, Bahuleyan CG, Vijayaraghavan G, et al. Five-year outcomes and predictors of death in patients hospitalized for heart failure in India: results from the Trivandrum heart failure registry. Int J Cardiol. 2021;326:139–43. DOI: https://doi.org/10.1016/j.ijcard.2020.10.012
Savarese G, Stolfo D, Sinagra G, Lund LH. Heart failure with mid-range or mildly reduced ejection fraction. Nat Rev Cardiol. 2022;19(2):100–16. DOI: https://doi.org/10.1038/s41569-021-00605-5
Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJ. Ejection fraction and mortality: a nationwide register-based cohort study of 499,153 women and men. Eur J Heart Fail. 2021;23(8):1331-40. DOI: https://doi.org/10.1002/ejhf.2047
Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC). Predictors of mortality in heart failure and development of a clinical risk score: a systematic review and meta-analysis. Eur Heart J. 2012;33(14):1750-7. DOI: https://doi.org/10.1093/eurheartj/ehr254
MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in congestive heart failure (MERIT-HF). Lancet. 1999;353(9169):2001-7. DOI: https://doi.org/10.1016/S0140-6736(99)04440-2
The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293-302. DOI: https://doi.org/10.1056/NEJM199108013250501